EPCAM and lung cancer: In our hospital, for the histological exploration of lung cancers at diagnosis, the EpCAM biomarker is not integrated because there is a high variability in expression level, while PD-L1 expression is the routine predictive biomarker for anti-cancer immunotherapy and is always integrated in all lung tumor explorations.